Daratumumab (Darzalex®) for use in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 09/10/17 |
| Rapid review completed | 27/11/17 |
| Rapid Review Outcome | A full pharmacoeconomic evaluation is recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 29/11/2017 |
| Pre-submission consultation with Applicant | 23/01/2018 |
| Submission received from Applicant | 21/09/2018 |
| Preliminary review sent to Applicant | 30/11/2018 |
| NCPE assessment re-commenced | 20/12/2018 |
| Factual accuracy sent to Applicant | 05/02/2019 |
| NCPE assessment re-commenced | 13/02/2019 |
| NCPE assessment completed | 15/03/2019 |
| NCPE assessment outcome |
The NCPE recommends that daratumumab combination (Darzalex®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. |